Eton Pharmaceuticals, Inc. (ETON)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Sean E. Brynjelsen | President, CEO & Director | 1.12M | -- | 1972 |
| Mr. James R. Gruber CPA | CFO, Treasurer & Secretary | 647.85k | -- | 1972 |
| Mr. David C. Krempa | Chief Business Officer | 647.85k | -- | 1989 |
| Ms. Ipek Erdogan-Trinkaus | Chief Commercial Officer | 435.94k | -- | 1982 |
| Danka Radosavljevic | Senior Vice President of Quality & Operations | -- | -- | -- |
| Mr. Scott Grossenbach | Senior Vice President of Sales Operations | -- | -- | -- |
| Mr. Kevin Guthrie | Executive VP of Commercial Operations | -- | -- | -- |
Eton Pharmaceuticals, Inc.
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Full Time Employees:
- 31
Description
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-400 for treating adrenal insufficiency; ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Corporate Governance
Upcoming Events
August 4, 2025 at 10:50 AM UTC - August 18, 2025 at 10:50 AM UTC
Eton Pharmaceuticals, Inc. Earnings Date